Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study.
作者： James G. Wall , Jacqueline K. Benedetti , Mark A. O'Rourke , Ronald B. Natale , John S. Macdonald
关键词:
摘要: Hepatocellular carcinoma remains a highly chemoresistant neoplasm. In this study of the topoisomerase I inhibitor topotecan response rate 13.9% (95% confidence interval 4.7%-29.5%) was obtained utilizing five consecutive day bolus infusion schedule. There were no complete responses and median survival only eight months. Furthermore, treatment with produced significant toxicity two-thirds patients experiencing life-threatening (grade 4) neutropenia. When used in dose schedule, does not appear to be effective for advanced hepatocellular carcinoma.
springer.com
sci-hub.se 参考文章(4)
E K Rowinsky, L B Grochow, C B Hendricks, D S Ettinger, A A Forastiere, L A Hurowitz, W P McGuire, S E Sartorius, B G Lubejko, S H Kaufmann, Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology. ,vol. 10, pp. 647- 656 ,(1992) , 10.1200/JCO.1992.10.4.647
James G Wall, Howard A Burris, Daniel D Von Hoff, Gladys Rodriguez, Rayna Kneuper-Hall, Don Shaffer, Timothy OʼRourke, Thomas Brown, Geoffrey Weiss, Gary Clark, Shirley McVea, Randall Johnson, Carl Friedman, Brian Smith, William S Mann, John Kuhn, A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs. ,vol. 3, pp. 337- 345 ,(1992) , 10.1097/00001813-199208000-00004
G.J. Creemers, B. Lund, J. Verweij, Topoisomerase I inhibitors: topotecan and irenotecan Cancer Treatment Reviews. ,vol. 20, pp. 73- 96 ,(1994) , 10.1016/0305-7372(94)90011-6
Gino Luporini, Roberto Labianca, Gianfranco Pancera, Medical treatment of hepatocellular carcinoma. Journal of Surgical Oncology. ,vol. 53, pp. 115- 118 ,(1993) , 10.1002/JSO.2930530531